Rapidly Establishing an Ultra-Cold Supply Chain of Vaccines in Israel: Evidence for the Efficacy of Inoculation to Mitigate the COVID-19 Pandemic

Vaccines (Basel). 2023 Feb 3;11(2):349. doi: 10.3390/vaccines11020349.

Abstract

The agenda of this research was to investigate how to mitigate the spread of coronaviruses by rapidly establishing an ultra-cold supply chain of vaccines. Data analysis was conducted by linear regression utilizing a dataset publicly available from the Israel Ministry of Health regarding the daily rates of people vaccinated, tested, hospitalized, etc., since the start of the pandemic. The data provide statistical evidence for the efficacy of the Pfizer vaccines in diminishing a wide variety of disease factors, such as the number of patients who were lightly, moderately, or severely sick, and daily deaths, as well as the rate of spread (R-ratio) and number/percentage of people infected. Insightfully, the data corroborate how the first and second doses of the vaccines were able to decrease the wave of COVID-19, which hit Israel in January 2021, while the booster third dose was able to diminish a subsequent COVID-19 wave occurring in Israel in July 2021.

Keywords: COVID-19; Israel; ultra-cold supply chain; vaccine efficacy.

Grants and funding

This research was supported by the Azrieli College of Engineering–Jerusalem Research Fund.